Can we make biologic therapy more affordable?
- PMID: 35666044
- DOI: 10.1002/alr.23039
Can we make biologic therapy more affordable?
Keywords: CRSwNP; anti-IL-4; aspirin exacerbated respiratory disease, biologic therapy; chronic rhinosinusitis with nasal polyposis; dupilumab; monoclonal antibody.
References
REFERENCES
-
- Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: a systematic review. Laryngoscope. 2015;125(7):1547-1556. https://doi.org/10.1002/lary.25180
-
- Yong M, Wu YQ, Howlett J, Ballreich J, Walgama E, Thamboo A. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2021;11(12):1626-1636. https://doi.org/10.1002/alr.22865
-
- Rathi VK, Scangas GA, Metson RB, Xiao R, Nshuti L, Dusetzina SB. Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population [published online ahead of print January 14, 2022]. Int Forum Allergy Rhinol. https://doi.org/10.1002/alr.22976
-
- Thamboo A, Kilty S, Witterick I, et al. Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2021;50(1):15. https://doi.org/10.1186/s40463-021-00493-2
-
- Roland LT, Smith TL, Schlosser RJ, et al. Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop. Int Forum Allergy Rhinol. 2020;10(9):1037-1042. https://doi.org/10.1002/alr.22633
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
